Quarterly Financial Summary for the Third Quarter of Fiscal Year Ending December 2026 [U.S. GAAP] (Consolidated)

Performance Overview

During the period, revenue reached 783,978 thousand USD, while operating loss amounted to -8,437,219 thousand USD and quarterly net loss was -7,743,359 thousand USD. Although research and development expenses were restrained to some extent, the company remained in an overall loss position. Cash and cash equivalents were 29.3 million USD, and shareholders' equity was reported as 41.094 hundred million USD, indicating continued pressure on the capital structure. The outlook for the next fiscal year has not been announced and may change depending on progress in partnership and out-licensing activities.

Outlook and Capital Strategy

The financial summary does not include consolidated earnings guidance for the fiscal year ending December 2026, and notes that the portion of R&D expenses borne may fluctuate depending on the terms of collaboration agreements. As a capital policy, the company maintains a framework to utilize a SEPA with Yorkville and the sale of common stock through Lucid, with costs and fees associated with issuance and sale of shares being incurred.